ID: ALA5219016

Max Phase: Preclinical

Molecular Formula: C71H108IN23O21S4

Molecular Weight: 1874.96

Associated Items:

Representations

Canonical SMILES:  C[C@@H](O)[C@@H]1NC(=O)[C@H]2NC(=O)[C@H](NC(=O)CN)CSSC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC(=O)O)NC1=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)c(I)c1)C(=O)N[C@@H](CCCN)C(=O)N[C@H](C(=O)N[C@H](CC(=O)N[C@@H](CCCNC(N)=O)C(=O)O)Cc1ccc(O)cc1)CSSC2(C)C

Standard InChI:  InChI=1S/C71H108IN23O21S4/c1-34(96)54-64(111)90-45(29-53(101)102)66(113)95-24-8-13-49(95)63(110)88-42(11-6-22-81-69(77)78)58(105)91-47-32-118-117-31-46(85-52(100)30-74)62(109)94-55(65(112)93-54)71(2,3)120-119-33-48(60(107)83-37(25-35-14-17-38(97)18-15-35)28-51(99)84-43(67(114)115)12-7-23-82-70(79)116)92-57(104)40(9-4-20-73)86-59(106)44(27-36-16-19-50(98)39(72)26-36)89-56(103)41(87-61(47)108)10-5-21-80-68(75)76/h14-19,26,34,37,40-49,54-55,96-98H,4-13,20-25,27-33,73-74H2,1-3H3,(H,83,107)(H,84,99)(H,85,100)(H,86,106)(H,87,108)(H,88,110)(H,89,103)(H,90,111)(H,91,105)(H,92,104)(H,93,112)(H,94,109)(H,101,102)(H,114,115)(H4,75,76,80)(H4,77,78,81)(H3,79,82,116)/t34-,37+,40+,41+,42+,43+,44+,45+,46-,47+,48+,49+,54+,55-/m1/s1

Standard InChI Key:  WKBMTJBSBLBSSP-TZHKBYJCSA-N

Associated Targets(Human)

Neuronal acetylcholine receptor; alpha9/alpha10 227 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 1874.96Molecular Weight (Monoisotopic): 1873.6018AlogP: #Rotatable Bonds:
Polar Surface Area: Molecular Species: HBA: HBD:
#RO5 Violations: HBA (Lipinski): HBD (Lipinski): #RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: CX LogP: CX LogD:
Aromatic Rings: Heavy Atoms: QED Weighted: Np Likeness Score:

References

1. Gajewiak J, Christensen SB, Dowell C, Hararah F, Fisher F, Huynh PN, Olivera BM, McIntosh JM..  (2021)  Selective Penicillamine Substitution Enables Development of a Potent Analgesic Peptide that Acts through a Non-Opioid-Based Mechanism.,  64  (13.0): [PMID:34142837] [10.1021/acs.jmedchem.1c00512]

Source